Answers are grounded in this paper and cite their sources.
Single center experience highlights insufficient immunosuppressive treatment in myasthenia gravis, suggesting a need for new therapies.
Only a small percentage of patients are eligible for the therapeutic program as an indication of insufficient immunosuppressive treatment of MG before hospitalization.
No takes yet. Share an insight, caveat, or question.
Rajczewski et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: